Recent Advances in the Development of Anticancer Drugs that Act against Signalling Pathways
Open Access
- 1 April 1994
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 80 (2) , 69-87
- https://doi.org/10.1177/030089169408000201
Abstract
Cancer can be considered a disease of deranged intracellular signalling. The intracellular signalling pathways that mediate the effects of oncogenes on cell growth and transformation present attractive targets for the development of new classes of drugs for the prevention and treatment of cancer. This is a new approach to developing anticancer drugs and the potential, as well as some of the problems, inherent in the approach are discussed. Anticancer drugs that produce their effects by disrupting signalling pathways are already in clinical trial. Some properties of these drugs, as well as other inhibitors of signalling pathways under development as potential anticancer drugs, are reviewed.Keywords
This publication has 170 references indexed in Scilit:
- The inhibition of phosphatidylinositol 3-kinase by quercetin and analogsBiochemical and Biophysical Research Communications, 1992
- Approaches to proto-oncogene and tumour suppressor gene identificationEuropean Journal Of Cancer, 1992
- Inhibition of protein kinase C by calphostin C is light-dependentBiochemical and Biophysical Research Communications, 1991
- Irreversible inhibition of v-src tyrosine kinase activity by herbimycin a and its abrogation by sulfhydryl compoundsBiochemical and Biophysical Research Communications, 1989
- Inhibition of tyrosine protein kinases by the antineoplastic agent adriamycinBiochemical and Biophysical Research Communications, 1989
- Permanent conversion of mouse and human cells transformed by activatedras orraf genes to apparently normal cells by treatment with the antibiotic azatyrosineMolecular Carcinogenesis, 1989
- Compound 48/80 is a potent inhibitor of phospholipase C and a dual modulator of phospholipase A2 from human plateletBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Aspirin inhibits phospholipase CBiochemical and Biophysical Research Communications, 1986
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986
- Polymyxin B is a more selective inhibitor for phospholipid-sensitive Ca2+-dependent protein kinase than for calmodulin-sensitive Ca2+-dependent protein kinaseBiochemical and Biophysical Research Communications, 1982